Stem Cell Advocates at the PepMed 2026 Peptide Conference Seek the FDA Openness That Compounded Peptides Have Gained
STAT reported on Monday, October 5, 2026 from PepMed 2026, a conference for regenerative health businesses held by the American Academy of Peptide Medicine, that stem cell entrepreneurs see the FDA's recent openness to compounded peptides as a model for bringing unapproved stem cell therapies out of the gray market. Entrepreneur Chuck Meeker predicted a series of FDA roundtables on stem cells before the end of the year; the FDA declined to say whether any were planned. Commercially sold, unapproved stem cell therapies have remained out of favor with the agency.